ST6GAL1 and colorectal carcinoma: As anticipated, we observed significant differences in the glycolysis pathways between the high and low expression groups, confirming our results that ST6GAL1 serves as an effective marker to stratify CRC patients into distinct metabolic subgroups, particularly regarding glycolysis (Figure S7F, Supporting Information).